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Abstract
Background: The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of
increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover
the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic
Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate
cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride
monotherapy from the health service provider perspective design.
Methods: An interactive Markov’s model was used to generate incremental cost per QALY and incremental cost
per life years gained. 2.9 million Men who were 50 years of age were fed into the model. The outcome measures
included: costs of drug treatment, consultation, acute urinary retention (AUR), transurethral resection of prostate
(TURP), hospitalisation post TURP, and quality adjusted life years (QALYs), incremental cost per life years gained, and
incremental cost per QALY gained.
Results: Fixed-dose combination of dutasteride and tamsulosin (FDCT) produced an Incremental cost-effectiveness
ratios of US$1481.92 per Quality adjusted for life-years saved.
Conclusion: Universal FDCT provision for Nigeria has major economic implications. This study in the context of its
limitations has demonstrated the cost effectiveness of FDCT for the long term treatment of patients with moderate
to severe BPH from the perspective of a developing country. Currently, there are few studies available to give
economic data evidence to policy makers in Nigeria which is applicable to developing countries with similar
economies. As such, the findings in this study will be relevant to policy makers in these countries.
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Background
Social Health Insurance Scheme was introduced in
Nigeria about a decade ago. It commenced with the enrol-
ment of the formal sector workers, however, there is plan
to extend it to the informal sector. However, the extent of
coverage is still limited. Some non-communicable diseases
are yet to be fully covered. Therefore, it became impera-
tive to explore cost effective measures to ensure that cer-
tain ailments not yet covered are considered to be
included in the benefit package.
While combination therapy has gained acceptance in
certain treatment settings in various countries [1–3]
questions regarding its cost effectiveness remains: Is
there any additional benefit in introducing fixed dose
combination therapy when compared with 5-alpha re-
ductase inhibitors alone? Are the benefits of fixed dose
combination therapy worth the additional expense of the
second prescription medication?
In addition, Nigeria being a middle income country
(gross domestic product of $574 billion) shares the same
economic health challenges as most countries in sub-
Saharan Africa and Asia that may have same economy
or poorer economic status. The cost effective measure
derived from this study will be relevant to policy makers
in such economies. This will enhance a robust health in-
surance scheme with a comprehensive package for the
informal sector.
About 22.3 % of the male population in Nigeria are di-
agnosed annually to have benign prostatic hyperplasia
(BPH) [4]. Currently, about 3,000,000 men are 50 years
old based on the projections from the 2006 population
census [5]. This number is likely to increase as life ex-
pectancy improves with improving economic status of
the population. The newly rebased gross domestic prod-
uct (GDP) could be an evidence of an improving econ-
omy in the country.
BPH manifest through lower urinary tract symptoms
(LUTS). If untreated, it can progress to complications
such as obstructive nephropathy, acute urinary retention
(AUR) and recurrent urinary retention [6, 7]. The main
reason for treating BPH is to improve symptoms and re-
duce risk of progression. For patients with mild symp-
toms; watchful waiting is the treatment option. However,
patients with moderate or severe BPH will require med-
ical treatment [8].
BPH currently is being treated with a combination of
tamsulosin and dutasteride (combination therapy) [9–11].
As the disease progresses, there may be need to offer ei-
ther minimally invasive therapy (transurethral resection of
the prostate) [12] or open prostatectomy. Studies have
demonstrated the efficacy of these combination therapy
(CT) in the management of BPH [13]. The current
pharmacological treatment protocol for LUTS caused by
BPH are alpha blockers (AB) such as tamsulosin and
5-alpha reductase inhibitors (5-ARI) such as dutasteride.
Tamsulosin relaxes the smooth muscles of the prostate and
bladder neck thereby increasing urine flow. Dutasteride re-
duces the vascularity and size of the prostate by inhibiting
formation of intra-prostatic dihydrotestosterone [13, 14].
The Nigerian standard treatment guideline recom-
mended alpha adrenergic blockers for the relief of symp-
toms in patients without prostate enlargement [15].
Though, this treatment option does not affect progres-
sion of disease. Also, ARI as either monotherapy or in
combination with AB are recommended for patients
with symptomatic BPH who have prostate enlargement.
Combination therapy effectively reduce risk of disease
progression.
On the other hand, the efficacy of dutasteride
monotherapy in the management of BPH has been proven
[10, 14, 16]. A 4-year randomised controlled trial designed
to evaluate the effectiveness of tamsulosin or dutasteride
monotherapy compared to combination of Avodart and
Tamsulosin; showed that combination therapy signifi-
cantly reduced the relative risk of AUR and surgery com-
pared to tamsulosin by 67.6 and 70.6 % respectively and
18.3 % for AUR and 31.1 % for surgery compared to
dutasteride [13].
Recently, there was a shift from combination therapy of
tamsulosin and dutasteride to a fixed- dose combination
of tamsulosin and dutasteride (FDCT). This shift, primar-
ily was intended to reduce cost and also make drug use
more convenient for the patients who will be on these
drugs for a long time. With the fixed dose, the patient
takes only a tablet daily compared to two tablets previ-
ously. The available brand in Nigeria is Duodart produced
and marketed by GSK pharmaceutical company.
The objective of this study was to estimate the long
term cost effectiveness of fixed- dose combination of
dutasteride and tamsulosin compared with dutasteride
monotherapy in the treatment of patients who present
with moderate or severe BPH from the health service




A discrete Markov model was developed to calculate the
costs, health benefits and cost effectiveness of FDCT
versus DM and to simulate the progression of BPH with
a cycle length of 1 year. The Markov model was selected
because BPH is a chronic condition with repeated clin-
ical events.
The model was run for ten (1-year) cycles and consists
of six mutually exclusive health states: (1) healthy; (2)
mild BPH symptoms; (3) moderate BPH symptoms; (4)
severe BPH symptoms; (5) Acute urinary retention; (6)
TURP and (7) death. The symptom severity were
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determined by the international prostate symptom score
(IPSS) and presence of complications such as acute urin-
ary retention. Based on the IPSS score, subjects are
grouped into Mild BPH (0–7), moderate BPH (8–19)
and severe BPH (20–35).
The IPSS is commonly used in evaluation of BPH
symptom severity. Also, since carcinoma of the prostate
mimics BPH, all patients with LUTS are usually
screened with serum total PSA. Those with elevated
PSA or abnormal digital rectal examination findings or
hypoechoic lesions on transrectal ultrasound undergo
transrectal prostate biopsy. Other important parameters
to be assessed as included in the CombAT study [13]
include age, prostate volume, and maximum urine
flow rate.
Cost effectiveness was calculated by dividing the differ-
ence in costs by the difference in health outcomes or
quality- adjusted- life-year (QALY) saved between the
two options of treatment to derive an incremental cost
effectiveness ratio (ICER). A discount factor of 60 % [17]
for both cost and effect was used.
We assumed that all patients included in this model
have BPH which is a lifetime disease. All patients is as-
sumed to enter the model in the early disease state of
Mild BPH.
Every year, people with BPH either remain in a health
state, move to a poorer health state or improve in their
health state based on a transition probability as shown
in Table 1. Table 2 shows baseline parameters depicting
transition probabilities associated with BPH treatment in
the model. The annual cost and utility values used in the
model are shown in Tables 3 and 4 respectively. Table 5
is a summary of the cost outcomes and incremental cost
effectiveness ratio for combination therapy compared
with dutastaride monotherapy.
The model structure used in this study is shown in
Fig. 1. The model was programmed using Microsoft
Excel (2007).
Patient’s population
To calculate the cost effectiveness of fixed dose combin-
ation of dutasteride and tamsulosin versus dutasteride, a
population of 2,862,363 who were 50 years of age based
on the last published Nigeria’s population statistics were
considered [18].
Healthy Subjects enter the model based on the pub-
lished incidence rate of BPH in Nigeria. The 50 year age
group was chosen because most patients become symp-
tomatic at that age [4, 19].
Outcome measures
The model estimates the following outcomes: cost of
drug treatment, cost of consultation, Cost of AUR, cost
of TURP, Cost of hospitalisation post TURP, and total
quality adjusted life years (QALYs), incremental cost per
life years gained, and incremental cost per QALY gained.
Cost and outcomes were discounted at 6 % per annum
based on the guidelines of World Health Organisation
for developing countries.
Treatment effects
The efficacy of the different interventions were derived
from the CombaT clinical study report [13].
The Combination of Avodart and Tamsulosin (CombAT)
study was a 4-years, multicentre, randomised, double-blind,
parallel-group study in 4844 men ≥50 years of age with a
clinical diagnosis of BPH, International Prostate Symptom
Score ≥12, prostate volume ≥30 cm(3), prostate-specific
antigen 1.5–10 ng/ml, and maximum urinary flow
rate (Q(max)) >5 and ≤15 ml/s with minimum voided
volume ≥125 ml.
Quality of life
In the absence of data on utility values in Nigeria, we
adopted the utility values derived from a Zimbabwe
population perspective.
Table 1 A brief summary of cost details of service provision in the two tertiary institutions
UNTH ($) JUTH ($)
TURP Drugs Clinic TURP Drugs Clinic
Surgical fees 153.67 165.76
Anaesthetic drugs/items 64.71 117.64
Antibiotic drugs 70.59 88.23
Investigations 58.82 88.23
Consumables 35.29 11.76
Feeding fees 29.14 14.7
Dutasteride (Avodart) 15.83/month 15.83/month
Fixed dose tamsulosin- dutasteride (Duodart) 24/month 24/month
Clinic consultations 47 47
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Sensitivity test
This evaluation is subject to uncertainty relating to the
data used in the study. The robustness of the ICER to
variation can be ascertained by sensitivity analysis.
One-way deterministic sensitivity analysis (DSA) was
performed to exclude deterministic, model structure and
parameter uncertainties in the study.
The DSA was accomplished by changing the discount
rates (0.01–0.06) while holding the remaining values in
the model constant; to test the uncertainty around the
model structure, treatment was commenced at health
states, moderate BPH and severe BPH respectively and
the variation from the baseline ICER noted. About 500,
000 people develop BPH annually in Nigeria. Though
the Markov model was populated with about 570,000
patients at the age of 50 years, a deterministic sensitivity
analysis was applied to both the duration of the cycle
and number of patients fed to the model. The utility
data used in the study were sourced from a country that
has slightly different socioeconomic background, giving
room to some degree of deterministic uncertainties. To
address this, a thorough deterministic analysis was
applied to the utility values. These values were varied
by ±20 % keeping other parameters constant noting
effect on baseline ICER. Also since cost data was pri-
marily obtained from two tertiary institutions; which
may introduce some deterministic uncertainties, these
values were subjected to deterministic analysis by
varying it by ±20 %.
Determining the Nigerian Government willingness to
pay threshold was challenging because it was not
available and could not be sourced from the literature.
However, the 2012 Gross National Income per capita
(GNI-PC) for Nigeria is US$2450 [20]. It has been sug-
gested that twice per capita GNI-PC can be used as a
reasonable threshold for determining cost effective ana-
lysis (8); therefore, the adopted threshold in this context
was US$2450 per QALY saved for cost effective analysis
of the new treatment.
Ethical clearance
The model was programmed in Microsoft Excel. No eth-
ics or consent were required for this study.
Results
The discounted cumulative costs associated with FDCT
and DM over 10 years were $US1.45 billion and US$855
million respectively; a difference of US$595 million.
The cumulative total of discounted QALYs associated
with FDCT was 18.8 million over 10 years compared to
18.4 million for DM, a difference of 401192 QALYs. The
calculated baseline ICERs were US$1481.92 per QALY
gained.
Sensitivity analysis
The greatest impact on ICER (extremely sensitive) was
seen when the assumption was altered and the model
was run for 5 and 15 years duration. Also, significant im-
pact was seen when the utility value for moderate BPH
was altered by ±20 % (Fig. 2). Variation of the other pa-
rameters did not affect the ICER significantly. The effect
of varying the health utility values by ±20 % is depicted
in the graph. There appears to be little effect with the
other utility parameters.
Table 3 Baseline parameters showing annual costs and utility
values associated with BPH treatment










Severe BPH 223.53 338.82
TURP 484.97 484.97
AUR 29.41 29.41
Table 2 Baseline parameters showing transition probabilities
associated with BPH treatment
Transitions (from-to) Average annual probability
Min, max Dutasteride therapy Combination therapy
Health to mild BPH 0.29 0.29
Mild BPH to moderate BPH 0.29 0.29
Moderate to severe BPH 0.16 0.058
Moderate/severe to AUR 0.13 0.04
Moderate/severe to TURP 0.16 0.056
TURP to repeat TURP 0.48 0.48
Severe to moderate BPH 0.46 0.49
Moderate to mild BPH 0.46 0.49
Death rate 0.013 0.013
Table 4 Baseline parameters showing utility values associated
with BPH treatment
Utility and disutility values used in the Markov model
Utility values Source





Disutility of AUR −0.145
Healthy 1.0
Sensitivity test
aThe quality of life was derived based on EQ-5D index score. Index score are
based on general population variations survey that used TTO methods
in Zimbabwe
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Probabilistic analysis was carried out (1000 simula-
tions) for both comparators. The cost effectiveness plane
(Fig. 3) shows that most times FDCT was more costly
but effective than DM as such most of the simulation
plots are found in the North-East and North-west quad-
rant of the plane.
The CEAC [21] shows the probability that any inter-
vention is cost effective conditional on the willingness to
pay per QALY. The curves also illustrate the degree of
uncertainty in the estimates. At a willingness to pay of
US$2450 per QALY, the probability of FDCT being cost
effective relative to DM was about 50 % (Fig. 4); which
was same for the calculated baseline ICER value
(US$1481.92 per QALY).
Discussion
In this economic evaluation, cost effectiveness was cal-
culated using the Markov modelling technique to aggre-
gate information on cost and progression of disease in
young adults. There was an assumption that the treat-
ment effect of FDCT lasted for 10 years and this gave
rise to an ICER value of US$1481.92 per QALY. How-
ever, extending the time horizon to 15 years, the ICER
value reduced to US$ 908.13 per QALY. At 10 years’
time horizon the result obtained was similar to the re-
sults published by Ismaila et al. [22], though done in a
different setting, which showed that FDCT was more
costly and more effective than DM. Furthermore, as the
time horizon was extended to 15 years the result ob-
tained was comparable to other studies conducted in
high income countries [22, 23]. The observed difference
in ICER value between this study and similar studies in
western countries could be explained by the low cost of
BPH related surgeries in Nigeria.
A closer look at a similar study conducted in the set-
ting of a Canadian population revealed a higher baseline
ICER of CAN$49,414 per QALY [22] compared to this
environment (US$1481.92 per QALY). The observed
Table 5 Cost, outcomes and incremental cost effectiveness ratio for combination therapy compared with dutasteride monotherapy
10-year horizon Total cost US$ Total QALYs Incremental costs Incremental QALYs Incremental cost
per QALY gained
Fixed dose therapy 1450279504.76 18836849.43 594535937.61 401192.00 1481.92
Dutasteride 855743567.15 18435657.43
15-year horizon
Combination 2194123563.22 23890352.46 852086147.24 938291.33 908.13
Dutasteride 1578867548.20 20879011.27
Fig. 1 Illustrative Markov model showing discrete health states and direction of transitions (arrows)
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difference is a reflection of the difference in setting.
Canada being a developed country with a higher GNI
per capita than Nigeria. It is expected that this difference
in GNI per capita may reflect cost of service provision in
these two countries which could explain the difference
in ICER. Also, in the context of the Nigeria’s health sys-
tem, public health institution service delivery is subsi-
dised by the government; though payment by the
informal sector is primarily out of pocket. As such, ser-
vice provision is still cheap compared to the more devel-
oped economies. This may explain why the baseline
ICER is much lower than that of Canada.
In addition, in the 10 year horizon, about
281,761TURPs and 492,176 AURs were avoided in the
FDCT group in our study. The total cost of treatment
in the FDCT arm was higher than the DM group (dif-
ference of US$ 594.5 million). Despite this difference,
FDCT was cost effective when the QALY -gained was
put into consideration. A similar study on cost effect-
iveness of FDCT and tamsulosin monotherapy con-
ducted by Geitona et al. [24] using the Greek health
system perspective revealed that 1758 TURPs and 972
AURs were avoided by using FDCT over a 4 year
horizon. Although, there was increase in disease man-
agement budget up to 7.9 % in 4 years, the study
showed a reduction in costs associated with the over-
all treatment of the disease. In particular, savings as-
sociated with the use of combination therapy arose
from the reduction in consultations, surgeries and
AURs. These savings was estimated to be €1.95 mil-
lion. These findings were comparable with ours,
though the comparators were different (tamsulosin in-
stead of DM); apparently a longer time horizon dem-
onstrated clearly the effectiveness of FDCT [24].
On the other hand, with respect to QALY gained,
about 2.8 million patients treated with FDCT in our
Fig. 2 Graphical representation of the deterministic sensitivity analysis result; depicting effects of parameters on baseline ICER
Fig. 3 Cost effectiveness plane showing the plots of ICERs generated from simulation
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study, gained 40,192 more QALYs than those treated
with DM within the 10 year horizon. This is higher than
the findings in the study by Bjerklund Johansen et al.
[25] which showed that in a group of 100 patients
treated for 4 years with FDCT, QALY gained was about
10 or 9 more QALYs than patients treated with dutaste-
ride monotherapy. When the model time horizon was
extended to the lifetime evaluation point, 100 patients
treated with FDCT accrued about 16 QALYs more than
those treated with DM. The observed difference is prob-
ably due to more number of patients being fed into our
model compared to their study and the difference in
model structure. However, that study [25] concluded
that compared with the 4-year outcomes, the lifetime
outcomes indicated that maintaining patients on com-
bination therapy provided additional health benefits and
a more favourable incremental cost-effective ratio than
with dutasteride and was most likely to provide the
greatest net monetary benefit at willingness to pay per
QALY gained above £5400.
There appears to be no consensus for acceptable will-
ingness to pay threshold in different regions. While the
UK’s National Institute for Clinical Excellence has
established a willingness-to-pay estimate that it applies
to cost-effectiveness evaluations (roughly £20 000 per
QALY gained), most European countries do not have
clearly established willingness to pay threshold [25].
This observed challenge is also applicable to Africa.
Although, there is no derived cost effectiveness thresh-
old in Africa, our model predicts that ICERs for FDCT
with dutasteride fall below thresholds that have been
suggested in the literature, and thus FDCT with
dutasteride is likely to be considered cost-effective for
management. Unfortunately, currently, there are few
works on cost effectiveness analysis on BPH treatment
in Africa. Apparently, there appears to be no publica-
tion in the public domain on cost effectiveness of
FDCT in BPH management in Africa based on Markov’s
model. This may be due to the new introduction of FDCT.
Some countries in Africa may not have adopted it as a
treatment protocol. This study may form the basis of fur-
ther studies in this area.
Furthermore, the sensitivity analysis showed that base-
line ICER was significantly sensitive to duration of cycle.
Taking a longer cycle (15 years) will result in reduction
of ICER implying almost similar outcome in terms of
cost for both FDCT and DM. Considering the life ex-
pectancy of Nigerian men which is about 55 years [20],
adopting a life time horizon of 15 years, may not be real-
istic for our setting.
Policy implication
Health insurance though introduced in Nigeria few
years ago still grapples with the economic burden of
providing full coverage. The major reason for this in-
sufficient funding borders on depending mainly on
contribution from the workers in formal sector (Social
health insurance) and augmentation by the govern-
ment. Effort to broaden the capital input is still in
progress. Some health insurance packages are being
explored currently to ensure enrolment of the infor-
mal sector.
Consequently, efficient use of the funds generated re-
mains imperative. BPH is a chronic ailment that could
span beyond a decade. Considering the vast population
of Nigerians and the number of individuals who may
eventually have BPH in their lifetime, any effort to re-
duce cost will interest policy makers.
Fig. 4 Cost- effectiveness acceptability curve for fixed dose combination therapy versus dutasteride
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Adopting FDCT though more expensive than DM is
more effective. Based on the baseline ICER of US$1481.92,
if policy makers should adopt a threshold ICER of
US$2450 per QALY, it will be cost effective to adopt
FDCT in the management of BPH in Nigeria.
With the current challenge of dwindling resources of
mono-product economies such as Nigeria, cost-saving
strategies and efficient utilisation of available funds can-
not be over-emphasized. Adopting FDCT, with the
afore-mentioned benefits, is a step in the right direction
to ensure a sustainable and cost-effective management
of BPH in this environment. This might encourage the
SHI as it exists currently in Nigeria consider the inclu-
sion of management of BPH in its benefit package.
Modelling to estimate treatment cost and effects; the
model structure; quality of parameters used and the as-
sumptions that have to be made are some of the limita-
tions of this study.
First, it was assumed that most likely duration of drug
effect was 10 years due to absence of long term data on
effectiveness of FDCT. If the mean effect of FDCT was
less than 10 years, the cost effectiveness of FDCT will
have been overestimated.
Also, assuming homogenous health status for each
health state; implying, transiting from a health state to
another will be based on transition probabilities. How-
ever, the existence of co-morbidity in some of the pa-
tients that could make them transit faster to other state
could not be controlled.
Inputting only direct cost can limit the utilisation of
this study for serious policy decision making because, it
lacks societal perspective. The use of utility values from
a different country may not exactly represent the context
of Nigeria. However, the effect of utility value on base-
line ICER when subjected to DSA was very minimal. A
detail CEA of FDCT is suggested in the future to include
a robust model which captures the ideal utility values.
Conclusion
Universal FDCT provision for Nigeria has major eco-
nomic implications. This study in the context of its limi-
tations has demonstrated the cost effectiveness of FDCT
for the long term treatment of patients with moderate to
severe BPH from the perspective of a developing coun-
try. Currently, there are few studies available to give eco-
nomic data evidence to policy makers in Nigeria which
is applicable to developing countries with similar econ-
omies. As such, the findings in this study will be relevant
to policy makers in these countries.
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